+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 85Years
MALE
ID07015138

A Randomized Phase III Trial Comparing Comprehensive Radiotherapy with Primary Tumor Radiotherapy in Men Aged 18 to 85 with Oligometastatic Prostate Cancer

Led by Peking University First Hospital · Updated on 2025-08-20

390

Participants Needed

3

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the survival benefits of comprehensive radiotherapy combined with primary tumor radiotherapy compared to primary tumor radiotherapy alone in men with newly diagnosed oligometastatic prostate cancer. This multicenter, randomized controlled phase III trial enrolls patients with up to 10 metastatic lesions confirmed by PSMA PET imaging. The study aims to provide clear evidence on progression-free survival and explore biomarkers to better predict treatment response, potentially influencing future treatment guidelines and quality of life improvements. Participants are randomly assigned in a 21 ratio to receive either comprehensive metastasis-directed radiotherapy targeting the primary tumor and all metastatic sites along with standard systemic therapy, or standard primary tumor radiotherapy with the same systemic therapy. Stratification factors include Gleason score and number of metastases. The primary endpoint is 3-year progression-free survival, with extensive follow-up visits scheduled at multiple time points up to 36 months post-radiotherapy. Secondary outcomes include overall survival, treatment discontinuation rates, quality of life, and adverse events. During the study, participants will undergo regular assessments including PSA testing, imaging, and quality of life questionnaires at specified intervals post-treatment. Researchers will monitor treatment effects, adverse events using CTCAE criteria, and progression through clinical and radiographic evaluations. The total participation period involves follow-up visits at 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, and 36 months after radiotherapy to thoroughly assess clinical outcomes and safety.

CONDITIONS

Brief Title

Comprehensive Versus Primary Tumor Radiotherapy in Oligometastatic Prostate Cancer

Research Team

H

Hong-zhen Li

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here